SEARCH

SEARCH BY CITATION

References

  • Akazawa C, Shigemoto R, Bessho Y, Nakanishi S, Mizuno N (1994). Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats. J Comp Neurol 347: 150160.
  • Alanine A, Bourson A, Büttelmann B, Gill R, Heitz M-P, Mutel V et al. (2003). 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 13: 31553159.
  • Albers GV, Goldstein LB, Hall D, Lesko LM (2001). Aptiganel hydrochloride in acute ischemic stroke – a randomized controlled trial. JAMA 286: 26732682.
  • Alberts IL, Nadassy K, Wodak SJ (1998). Analysis of zinc binding sites in protein crystal structures. Protein Sci 7: 17001716.
  • Alexander S, Mathie A, Peters J (2008). Guide to receptors and channels (GRAC), 3rd edn (2008 revision). Br J Pharmacol 153 (Suppl. 2): S1S209.
  • Araneda RC, Lan JY, Zheng X, Zukin RS, Bennett MV (1999). Spermine and arcaine block and permeate N-methyl-D-aspartate receptor channels. Biophys J 76: 28992911.
  • Banke TG, Dravid SM, Traynelis SF (2005). Protons trap NR1/NR2B NMDA receptors in a nonconducting state. J Neurosci 25: 4251.
  • Belelli D, Lambert JJ (2005). Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 6: 565575.
  • Benveniste M, Mayer ML (1993). Multiple effects of spermine on N-methyl-D-aspartic acid receptor responses of rat cultured hippocampal neurones. J Physiol 464: 131163.
  • Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47: 351354.
  • Borza I, Bozo E, Barta-Szalai G, Kiss C, Tarkanyi G, Demeter A et al. (2007). Selective NR1/2B N-methyl-D-aspartate receptor antagonists among indole-2-carboxamides and benzimidazole-2-carboxamides. J Med Chem 50: 901914.
  • Borza I, Domany G (2006). NR2B selective NMDA antagonists: the evolution of the ifenprodil-type pharmacophore. Curr Top Med Chem 6: 687695.
  • Borza I, Kolok S, Gere A, Nagy J, Fodor L, Galgoczy K et al. (2006). Benzimidazole-2-carboxamides as novel NR2B selective NMDA receptor antagonists. Bioorg Med Chem Lett 16: 46384640.
  • Bowlby MR (1993). Pregnenolone sulfate potentiation of N-methyl-D-aspartate receptor channels in hippocampal-neurons. Mol Pharmacol 43: 813819.
  • Boyce S, Wyatt A, Webb JK, O'Donnell R, Mason G, Rigby M et al. (1999). Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 38: 611623.
  • Boyce SRRC, Wheeldon A, Rupniak NM, Hill RG (2002). Antinociceptive activity of the NMDA NR2B receptor subtype selective antagonist CP-101,606 in a new rat visceral pain assay. In IASP Meeting San Diego, Abstract ID: 848–P118.
  • Büttelmann B, Alanine A, Bourson A, Gill R, Heitz M-P, Mutel V et al. (2003). 2-(3,4-Dihydro-1H-isoquinolin-2yl)-pyridines as a novel class of NR1/2B subtype selective NMDA receptor antagonists. Bioorg Med Chem Lett 13: 829832.
  • Carron C, Jullien A, Bucher B (1971). Synthesis and pharmacological properties of a series of 2-piperidino alkanol derivatives. Arzneimittelforschung 21: 19921998.
  • Carter C, Benavides J, Legendre P, Vincent JD, Noel F, Thuret F et al. (1988). Ifenprodil and SL 82.0715 as cerebral anti-ischemic agents. II. Evidence for N-methyl-D-aspartate receptor antagonist properties. J Pharmacol Exp Ther 247: 12221232.
  • Chang HR, Kuo CC (2008). The activation gate and gating mechanism of the NMDA receptor. J Neurosci 28: 15461556.
  • Chaperon F, Muller W, Auberson YP, Tricklebank MD, Neijt HC (2003). Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit. Behav Pharmacol 14: 477487.
  • Chazot PL (2004). The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr Med Chem 11: 389396.
  • Chen M, Lu TJ, Chen XJ, Zhou Y, Chen Q, Feng XY et al. (2008). Differential roles of NMDA receptor subtypes in ischemic neuronal cell death and ischemic tolerance. Stroke 39: 30423048.
  • Chen N, Moshaver A, Raymond LA (1997). Differential sensitivity of recombinant N-methyl-D-aspartate receptor subtypes to zinc inhibition. Mol Pharmacol 51: 10151023.
  • Chenard BL, Bordner J, Butler TW, Chambers LK, Collins MA, Decosta DL et al. (1995). (1s,2s)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol – a potent new neuroprotectant which blocks N-methyl-D-aspartate responses. J Med Chem 38: 31383145.
  • Chenard BL, Menniti FS (1999). Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des 5: 381404.
  • Chizh BA (2007). Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways. J Psychopharmacol 21: 259271.
  • Chizh BA, Headley PM, Tzschentke TM (2001). NMDA receptor antagonists as analgesics: focus on the NR2B subtype. Trends Pharmacol Sci 22: 636642.
  • Choi YB, Lipton SA (1999). Identification and mechanism of action of two histidine residues underlying high-affinity Zn2+ inhibition of the NMDA receptor. Neuron 23: 171180.
  • Claiborne CF, McCauley JA, Libby BE, Curtis NR, Diggle HJ, Kulagowski JJ et al. (2003). Orally efficacious NR2B-selective NMDA receptor antagonists. Bioorg Med Chem Lett 13: 697700.
  • Cull-Candy SG, Leszkiewicz DN (2004). Role of distinct NMDA receptor subtypes at central synapses. Sci STKE 2004: re16.
  • Curtis NR, Diggle HJ, Kulagowski JJ, London C, Grimwood S, Hutson PH et al. (2003). Novel N1-(benzyl)cinnamamidine derived NR2B subtype-selective NMDA receptor antagonists. Bioorg Med Chem Lett 13: 693696.
  • Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN et al. (2001). Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 16: 515520.
  • Dingledine R, Borges K, Bowie D, Traynelis SF (1999). The glutamate receptor ion channels. Pharmacol Rev 51: 761.
  • Von Engelhardt J, Coserea I, Pawlak V, Fuchs EC, Kohr G, Seeburg PH et al. (2007). Excitotoxicity in vitro by NR2A- and NR2B-containing NMDA receptors. Neuropharmacology 53: 1017.
  • Von Engelhardt J, Doganci B, Jensen V, Hvalby O, Gongrich C, Taylor A et al. (2008). Contribution of hippocampal and extra-hippocampal NR2B-containing NMDA receptors to performance on spatial learning tasks. Neuron 60: 846860.
  • Farkas S, Horvath C, Galgoczy L, Felmerai E, Karsai E, Saghhy K et al. (2003). RGH-896 is a novel potent and selective NR2B-NMDA antagonist with efficacy in neuropathic pain models. In Society for Neuroscience Meeting, Program # 382.8.
  • Farrant M, Feldmeyer D, Takahashi T, Cullcandy SG (1994). NMDA-receptor channel diversity in the developing cerebellum. Nature 368: 335339.
  • Fayyazuddin A, Villarroel A, Le Goff A, Lerma J, Neyton J (2000). Four residues of the extracellular N-terminal domain of the NR2A subunit control high-affinity Zn2+ binding to NMDA receptors. Neuron 25: 683694.
  • Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E et al. (1997). Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther 283: 12851292.
  • Furukawa H, Gouaux E (2003). Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. Embo J 22: 28732885.
  • Furukawa H, Singh SK, Mancusso R, Gouaux E (2005). Subunit arrangement and function in NMDA receptors. Nature 438: 185192.
  • Gallagher MJ, Huang H, Pritchett DB, Lynch DR (1996). Interactions between ifenprodil and the NR2B subunit of the N-methyl-D-aspartate receptor. J Biol Chem 271: 96039611.
  • Gielen M, Le Goff A, Stroebel D, Johnson JW, Neyton J, Paoletti P (2008). Structural rearrangements of NR1/NR2A NMDA receptors during allosteric inhibition. Neuron 57: 8093.
  • Giffard RG, Monyer H, Christine CW, Choi DW (1990). Acidosis reduces NMDA receptor activation, glutamate neurotoxicity, and oxygen-glucose deprivation neuronal injury in cortical cultures. Brain Res 506: 339342.
  • Gill R, Alanine A, Bourson A, Buttelmann B, Fischer G, Heitz MP et al. (2002). Pharmacological characterization of Ro 63-1908 (1-[2-(4-hydroxy-phenoxy)-ethyl]-4-(4-methyl-benzyl)-piperidin-4-ol), a novel subtype-selective N-methyl-D-aspartate antagonist. J Pharmacol Exp Ther 302: 940948.
  • Gogas KR (2006). Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr Opin Pharmacol 6: 6874.
  • Guscott MR, Clarke HF, Murray F, Grimwood S, Bristow LJ, Hutson PH (2003). The effect of (+/-)-CP-101,606, an NMDA receptor NR2B subunit selective antagonist, in the Morris watermaze. Eur J Pharmacol 476: 193199.
  • Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH et al. (2006). Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12: 824828.
  • Han X, Tomitori H, Mizuno S, Higashi K, Full C, Fukiwake T et al. (2008). Binding of spermine and ifenprodil to a purified, soluble regulatory domain of the N-methyl-d-aspartate receptor. J Neurochem 107: 15661577.
  • Hardingham GE, Bading H (2003). The Yin and Yang of NMDA receptor signalling. Trends Neurosci 26: 8189.
  • Hatton CJ, Paoletti P (2005). Modulation of triheteromeric NMDA receptors by N-terminal domain ligands. Neuron 46: 261274.
  • Herin GA, Aizenman E (2004). Amino terminal domain regulation of NMDA receptor function. Eur J Pharmacol 500: 101111.
  • Higgins GA, Ballard TM, Enderlin M, Haman M, Kemp JA (2005). Evidence for improved performance in cognitive tasks following selective NR2B NMDA receptor antagonist pre-treatment in the rat. Psychopharmacology (Berl) 179: 8598.
  • Horak M, Vlcek K, Chodounska H, Vyklicky L (2006). Subtype-dependence of N-methyl-D-aspartate receptor modulation by pregnenolone sulfate. Neuroscience 137: 93102.
  • Horak M, Vlcek K, Petrovic M, Chodounska H, Vyklicky L (2004). Molecular mechanism of pregnenolone sulfate action at NR1/NR2B receptors. J Neurosci 24: 1031810325.
  • Horvath C (2004). 3rd World Cong. World Inst. Pain: Barcelona. September 21–25.
  • Hosie AM, Wilkins ME, Da Silva HM, Smart TG (2006). Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites. Nature 444: 486489.
  • Huggins DJ, Grant GH (2005). The function of the amino terminal domain in NMDA receptor modulation. J Mol Graph Model 23: 381388.
  • Jang MK, Mierke DF, Russek SJ, Farb DH (2004). A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity. Proc Natl Acad Sci USA 101: 81988203.
  • Javitt DC (2008). Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 63: 68.
  • Kashiwagi K, Fukuchi J, Chao J, Igarashi K, Williams K (1996). An aspartate residue in the extracellular loop of the N-methyl-D-aspartate receptor controls sensitivity to spermine and protons. Mol Pharmacol 49: 11311141.
  • Kashiwagi K, Pahk AJ, Masuko T, Igarashi K, Williams K (1997). Block and modulation of N-methyl-D-aspartate receptors by polyamines and protons: role of amino acid residues in the transmembrane and pore-forming regions of NR1 and NR2 subunits. Mol Pharmacol 52: 701713.
  • Kemp JA, Kew JNC, Gill R (1999). NMDA receptor antagonists and their potential as neuroprotective agents. In: JonasP, MonyerH (eds). Handbook of Experimental Pharmacology Volume 141. Ionotropic Glutamate Receptors in the CNS. Springer: Berlin, pp. 495527.
  • Kew JN, Kemp JA (1998). An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. J Physiol 512 (Pt 1): 1728.
  • Kew JN, Trube G, Kemp JA (1996). A novel mechanism of activity-dependent NMDA receptor antagonism describes the effect of ifenprodil in rat cultured cortical neurones. J Physiol 497 (Pt 3): 761772.
  • Kiss L, Cheng G, Bednar B, Bednar RA, Bennett PB, Kane SA et al. (2005). In vitro characterization of novel NR2B selective NMDA receptor antagonists. Neurochem Int 46: 453464.
  • Köhr G (2006). NMDA receptor function: subunit composition versus spatial distribution. Cell Tissue Res 326: 439446.
  • Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R et al. (2005). Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 179: 303309.
  • Lees KR, Asplund K, Carolei A, Davis SM, Diener HC, Kaste M et al. (2000). Glycine antagonist (gavestinel) in neuroprotection (GAIN International) in patients with acute stroke: a randomised controlled trial. GAIN International Investigators. Lancet 355: 19491954.
  • Lerma J (1992). Spermine regulates N-methyl-D-aspartate receptor desensitization. Neuron 8: 343352.
  • Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR et al. (2003). Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington disease. Neurobiol Aging 24: 11131121.
  • Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW et al. (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27: 28462857.
  • Lopez de Armentia M, Sah P (2003). Development and subunit composition of synaptic NMDA receptors in the amygdale: NR2B synapses in the adult central amygdala. J Neurosci 23: 68766883.
  • Loschmann PA, De Groote C, Smith L, Wullner U, Fischer G, Kemp JA et al. (2004). Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Exp Neurol 187: 8693.
  • Low CM, Lyuboslavsky P, French A, Le P, Wyatte K, Thiel WH et al. (2003). Molecular determinants of proton-sensitive N-methyl-D-aspartate receptor gating. Mol Pharmacol 63: 12121222.
  • Low CM, Zheng F, Lyuboslavsky P, Traynelis SF (2000). Molecular determinants of coordinated proton and zinc inhibition of N-methyl-D-aspartate NR1/NR2A receptors. Proc Natl Acad Sci USA 97: 1106211067.
  • Lu WY, Xiong ZG, Orser BA, MacDonald JF (1998). Multiple sites of action of neomycin, Mg2+ and spermine on the NMDA receptors of rat hippocampal CA1 pyramidal neurones. J Physiol 512 (Pt 1): 2946.
  • Luo J, Wang Y, Yasuda RP, Dunah AW, Wolfe BB (1997). The majority of N-methyl-D-aspartate receptor complexes in adult rat cerebral cortex contain at least three different subunits (NR1/NR2A/NR2B). Mol Pharmacol 51: 7986.
  • Ma QP, Hargreaves RJ (2000). Localization of N-methyl-D-aspartate NR2B subunits on primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats. Neuroscience 101: 699707.
  • McCauley JA (2007). NR2B subtype-selective NMDA receptor antagonists. In 3rd Anglo-Swedish Medicinal Chemistry Symposium. Are, Sweden.
  • McCauley JA, Bednar RA, Bednar B, Butcher JW, Claiborne CF, Claremon DA et al. (2008). NR2B subtype-selective NMDA receptor antagonists. In Abstracts – 236th ACS National Meeting. Philadelphia, PA, August 17–21, 2008.
  • McGurk JF, Bennett MV, Zukin RS (1990). Polyamines potentiate responses of N-methyl-D-aspartate receptors expressed in xenopus oocytes. Proc Natl Acad Sci USA 87: 99719974.
  • Maeng S, Zarate CA Jr (2007). The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects. Curr Psychiatry Rep 9: 467474.
  • Makani S, Chesler M (2007). Endogenous alkaline transients boost postsynaptic NMDA receptor responses in hippocampal CA1 pyramidal neurons. J Neurosci 27: 74387446.
  • Malayev A, Gibbs TT, Farb DH (2002). Inhibition of the NMDA response by pregnenolone sulphate reveals subtype selective modulation of NMDA receptors by sulphated steroids. Br J Pharmacol 135: 901909.
  • Malherbe P, Mutel V, Broger C, Perin-Dureau F, Kemp JA, Neyton J et al. (2003). Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket. J Pharmacol Exp Ther 307: 897905.
  • Martel MA, Wyllie DJ, Hardingham GE (2009). In developing hippocampal neurons, NR2B-containing N-methyl-d-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 158: 334343.
  • Masuko T, Kashiwagi K, Kuno T, Nguyen ND, Pahk AJ, Fukuchi J et al. (1999). A regulatory domain (R1-R2) in the amino terminus of the N-methyl-D-aspartate receptor: effects of spermine, protons, and ifenprodil, and structural similarity to bacterial leucine/isoleucine/valine binding protein. Mol Pharmacol 55: 957969.
  • Mayer ML (2006). Glutamate receptors at atomic resolution. Nature 440: 456462.
  • Merchant RE, Bullock MR, Carmack CA, Shah AK, Wilner KD, Ko G et al. (1999). A double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of CP-101,606 in patients with a mild or moderate traumatic brain injury. Ann N Y Acad Sci 890: 4250.
  • Montastruc JL, Rascol O, Senard JM, Rascol A (1992). A pilot study of N-methyl-D-aspartate (NMDA) antagonist in Parkinson's disease. J Neurol Neurosurg Psychiatry 55: 630631.
  • Mony L, Krzaczkowski L, Leonetti M, Goff AL, Alarcon K, Neyton J et al. (2009). Structural basis of NR2B-selective antagonist recognition by N-methyl-D-aspartate receptors. Mol Pharmacol 75: 6074.
  • Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994). Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12: 529540.
  • Morris GF, Bullock R, Marshall SB, Marmarou A, Maas A, Marshall LF (1999). Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. J Neurosurg 91: 737743.
  • Mott DD, Doherty JJ, Zhang S, Washburn MS, Fendley MJ, Lyuboslavsky P et al. (1998). Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. Nat Neurosci 1: 659667.
  • Neyton J, Paoletti P (2006). Relating NMDA receptor function to receptor subunit composition: limitations of the pharmacological approach. J Neurosci 26: 13311333.
  • Ng FM, Geballe MT, Snyder JP, Traynelis SF, Low CM (2008). Structural insights into phenylethanolamines high-affinity binding site in NR2B from binding and molecular modeling studies. Mol Brain 1: 16.
  • Ng FM, Soh W, Geballe MT, Low CM (2007). Improving solubility of NR2B amino-terminal domain of N-methyl-d-aspartate receptor expressed in Escherichia coli. Biochem Biophys Res Commun 362: 6974.
  • Nicholson KL, Mansbach RS, Menniti FS, Balster RL (2007). The phencyclidine-like discriminative stimulus effects and reinforcing properties of the NR2B-selective N-methyl-D-aspartate antagonist CP-101 606 in rats and rhesus monkeys. Behav Pharmacol 18: 731743.
  • Nikam SS, Meltzer LT (2002). NR2B selective NMDA receptor antagonists. Curr Pharm Des 8: 845855.
  • Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M et al. (2008). Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord 23: 18601866.
  • O'Hara PJ, Sheppard PO, Thogersen H, Venezia D, Haldeman BA, McGrane V et al. (1993). The ligand-binding domain in metabotropic glutamate receptors is related to bacterial periplasmic binding-proteins. Neuron 11: 4152.
  • Pahk AJ, Williams K (1997). Influence of extracellular pH on inhibition by ifenprodil at N-methyl-D-aspartate receptors in Xenopus oocytes. Neurosci Lett 225: 2932.
  • Paoletti P, Ascher P, Neyton J (1997). High-affinity zinc inhibition of NMDA NR1-NR2A receptors. J Neurosci 17: 57115725.
  • Paoletti P, Neyton J (2007). NMDA receptor subunits: function and pharmacology. Curr Opin Pharmacol 7: 3947.
  • Paoletti P, Neyton J, Ascher P (1995). Glycine-independent and subunit-specific potentiation of NMDA responses by extracellular Mg2+. Neuron 15: 11091120.
  • Paoletti P, Perin-Dureau F, Fayyazuddin A, Goff AL, Callebaut I, Neyton J (2000). Molecular organization of a zinc binding N-terminal modulatory domain in a NMDA receptor subunit. Neuron 28: 911925.
  • Paoletti P, Vergnano AM, Barbour B, Casado M (2009). Zinc at glutamatergic synapses. Neuroscience 158: 126136.
  • Park-Chung M, Wu FS, Purdy RH, Malayev AA, Gibbs TT, Farb DH (1997). Distinct sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated steroids. Mol Pharmacol 52: 11131123.
  • Parkchung MJ, Wu FS, Farb DH (1994). 3-alpha-hydroxy-5-beta-pregnan-20-one sulfate – a negative modulator of the NMDA-induced current in cultured neurons. Mol Pharmacol 46: 146150.
  • Parsons CG, Stoffler A, Danysz W (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology 53: 699723.
  • Perin-Dureau F, Rachline J, Neyton J, Paoletti P (2002). Mapping the binding site of the neuroprotectant ifenprodil on NMDA receptors. J Neurosci 22: 59555965.
  • Petrovic M, Sedlacek M, Horak M, Chodounska H, Vyklicky L (2005). 20-oxo-5 beta-pregnan-3 alpha-yl sulfate is a use-dependent NMDA receptor inhibitor. J Neurosci 25: 84398450.
  • Pinheiro PS, Mulle C (2008). Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat Rev Neurosci 9: 423436.
  • Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28: 631637.
  • Rachline J, Perin-Dureau F, Goff AL, Neyton J, Paoletti P (2005). The micromolar zinc-binding domain on the NMDA receptor subunit NR2B. J Neurosci 25: 308317.
  • Robel P, Baulieu EE (1994). Neurosteroids biosynthesis and function. Trends Endocrinol Metab 5: 18.
  • Rock DM, MacDonald RL (1992). Spermine and related polyamines produce a voltage-dependent reduction of N-methyl-D-aspartate receptor single-channel conductance. Mol Pharmacol 42: 157164.
  • Rock DM, Macdonald RL (1995). Polyamine regulation of N-methyl-D-aspartate receptor channels. Annu Rev Pharmacol Toxicol 35: 463482.
  • Rumbaugh G, Prybylowski K, Wang JF, Vicini S (2000). Exon 5 and spermine regulate deactivation of NMDA receptor subtypes. J Neurophysiol 83: 13001306.
  • Saltarelli MD, Weaver JJ, Hsu C, Bednar MM (2004). Randomized double-blind, placebo-controlled study to evaluate the safety and efficacy of CP-101,606 (traxoprodil), an NR2B-selective N-methyl D-aspartate receptor antagonist, in subjects with acute ischemic stroke. Stroke 35: 241241.
  • Sang CN, Weaver JJ, Jinga L, Wouden J, Saltarelli MD (2003). The NR2B subunit-selective NMDA receptor antagonist CP-101,606 reduces pain intensity in patients with central and peripheral neuropathic pain. In Society for Neuroscience, Meeting. Program # 814.9.
  • Scimemi A, Fine A, Kullmann DM, Rusakov DA (2004). NR2B-containing receptors mediate cross talk among hippocampal synapses. J Neurosci 24: 47674777.
  • Silver RA, Traynelis SF, Cull-Candy SG (1992). Rapid-time-course miniature and evoked excitatory currents at cerebellar synapses in situ. Nature 355: 163166.
  • Steece-Collier K, Chambers LK, Jaw-Tsai SS, Menniti FS, Greenamyre JT (2000). Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-d-aspartate receptors. Exp Neurol 163: 239243.
  • Suetake-Koga S, Shimazaki T, Takamori K, Chaki S, Kanuma K, Sekiguchi Y et al. (2006). In vitro and antinociceptive profile of HON0001, an orally active NMDA receptor NR2B subunit antagonist. Pharmacol Biochem Behav 84: 134141.
  • Sun Y, Olson R, Horning M, Armstrong N, Mayer M, Gouaux E (2002). Mechanism of glutamate receptor desensitization. Nature 417: 245253.
  • Tahirovic YA, Geballe M, Gruszecka-Kowalik E, Myers SJ, Lyuboslavsky P, Le P et al. (2008). Enantiomeric propanolamines as selective N-methyl-D-aspartate 2B receptor antagonists. J Med Chem 51: 55065521.
  • Tamiz AP, Cai SX, Zhou Z-L, Yuen P-W, Shelkun RM, Whittemore ER et al. (1999). Structure-activity relationship of N(Phenylalkyl)cinnamides as novel NR2B subtype-selective NMDA receptor antagonists. J Med Chem 42: 34123420.
  • Tan PH, Yang LC, Shih HC, Lan KC, Cheng JT (2005). Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 12: 5966.
  • Tang CM, Dichter M, Morad M (1990). Modulation of the N-methyl-D-aspartate channel by extracellular H+. Proc Natl Acad Sci USA 87: 64456449.
  • Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M et al. (1999). Genetic enhancement of learning and memory in mice. Nature 401: 6369.
  • Taniguchi K, Shinjo K, Mizutani M, Shimada K, Ishikawa T, Menniti FS et al. (1997). Antinociceptive activity of CP-101,606, an NMDA receptor NR2B subunit antagonist. Br J Pharmacol 122: 809812.
  • Traynelis SF, Burgess MF, Zheng F, Lyuboslavsky P, Powers JL (1998). Control of voltage-independent zinc inhibition of NMDA receptors by the NR1 subunit. J Neurosci 18: 61636175.
  • Traynelis SF, Cull-Candy SG (1990). Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature 345: 347350.
  • Traynelis SF, Hartley M, Heinemann SF (1995). Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science 268: 873876.
  • Trube G, Ehrhard P, Malherbe P, Huber G (1996). The selectivity of Ro25-6981 for NMDA receptor subtypes expressed in Xenopus oocytes. Soc Neurosci Abstr 22: 693694.
  • Umbricht D, Krljes S (2005). Mismatch negativity in schizophrenia: a meta-analysis. Schizophr Res 76: 123.
  • Vogt K, Mellor J, Tong G, Nicoll R (2000). The actions of synaptically released zinc at hippocampal mossy fiber synapses. Neuron 26: 187196.
  • Vyklicky L Jr, Vlachova V, Krusek J (1990). The effect of external pH changes on responses to excitatory amino acids in mouse hippocampal neurones. J Physiol 430: 497517.
  • Wang LY, MacDonald JF (1995). Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones. J Physiol 486: 8395.
  • Watanabe M, Inoue Y, Sakimura K, Mishina M (1992). Developmental changes in distribution of NMDA receptor channel subunit mRNAs. Neuroreport 3: 11381140.
  • Watanabe M, Inoue Y, Sakimura K, Mishina M (1993). Distinct distributions of five N-methyl-D-aspartate receptor channel subunit mRNAs in the forebrain. J Comp Neurol 338: 377390.
  • Watanabe M, Mishina M, Inoue Y (1994). Distinct spatiotemporal distributions of the N-methyl-D-aspartate receptor channel subunit mRNAs in the mouse cervical cord. J Comp Neurol 345: 314319.
  • Weaver CE, Land MB, Purdy RH, Richards KG, Gibbs TT, Farb DH (2000). Geometry and charge determine pharmacological effects of steroids on N-methyl-D-aspartate receptor-induced Ca2+ accumulation and cell death. J Pharm Exp Ther 293: 747754.
  • Wei F, Wang GD, Kerchner GA, Kim SJ, Xu HM, Chen ZF et al. (2001). Genetic enhancement of inflammatory pain by forebrain NR2B overexpression. Nat Neurosci 4: 164169.
  • Wessell RH, Ahmed SM, Menniti FS, Dunbar GL, Chase TN, Oh JD (2004). NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharm 47: 184194.
  • Williams K (1993). Ifenprodil discriminates subtypes of the N-methyl-D-aspartate receptor-selectivity and mechanisms at recombinant heteromeric receptors. Mol Pharmacol 44: 851859.
  • Williams K (1994a). Mechanisms influencing stimulatory effects of spermine at recombinant N-methyl-D-aspartate receptors. Mol Pharmacol 46: 161168.
  • Williams K (1994b). Subunit-specific potentiation of recombinant N-methyl-D-aspartate receptors by histamine. Mol Pharmacol 46: 531541.
  • Williams K, Kashiwagi K, Fukuchi J, Igarashi K (1995). An acidic amino acid in the N-methyl-D-aspartate receptor that is important for spermine stimulation. Mol Pharmacol 48: 10871098.
  • Williams K, Zappia AM, Pritchett DB, Shen YM, Molinoff PB (1994). Sensitivity of the N-methyl-D-aspartate receptor to polyamines is controlled by NR2 subunits. Mol Pharmacol 45: 803809.
  • Wilson AW, Medhurst SJ, Dixon CI, Bontoft NC, Winyard LA, Brackenborough KT et al. (2006). An animal model of chronic inflammatory pain: pharmacological and temporal differentiation from acute models. Eur J Pain 10: 537549.
  • Wong E, Ng FM, Yu CY, Lim P, Lim LH, Traynelis SF et al. (2005). Expression and characterization of soluble amino-terminal domain of NR2B subunit of N-methyl-D-aspartate receptor. Protein Sci 14: 22752283.
  • Woo TUW, Kim AM, Viscidi E (2008). Disease-specific alterations in glutamatergic neurotransmission on inhibitory interneurons in the prefrontal cortex in schizophrenia. Brain Res 1218: 267277.
  • Woodhall G, Evans DI, Cunningham MO, Jones RS (2001). NR2B-containing NMDA autoreceptors at synapses on entorhinal cortical neurons. J Neurophysiol 86: 16441651.
  • Wu FS, Gibbs TT, Farb DH (1991). Pregnenolone sulfate – a positive allosteric modulator at the N-methyl-D-aspartate receptor. Mol Pharmacol 40: 333336.
  • Zarate CA Jr, Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA et al. (2006). A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry 163: 153155.
  • Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P et al. (2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33: 849860.
  • Zhang L, Zheng X, Paupard MC, Wang AP, Santchi L, Friedman LK et al. (1994). Spermine potentiation of recombinant N-methyl-D-aspartate receptors is affected by subunit composition. Proc Natl Acad Sci USA 91: 1088310887.
  • Zhou M, Baudry M (2006). Developmental changes in NMDA neurotoxicity reflect developmental changes in subunit composition of NMDA receptors. J Neurosci 26: 29562963.